title: Deoxyhypusine hydroxylase from Plasmodium vivax, the neglected human malaria parasite: molecular cloning, expression and specific inhibition by the 5-LOX inhibitor zileuton.
abstract: Primaquine, an 8-aminoquinoline, is the only drug which cures the dormant hypnozoites of persistent liver stages from P. vivax. Increasing resistance needs the discovery of alternative pathways as drug targets to develop novel drug entities. Deoxyhypusine hydroxylase (DOHH) completes hypusine biosynthesis in eukaryotic initiation factor (eIF-5A) which is the only cellular protein known to contain the unusual amino acid hypusine. Modified EIF-5A is important for proliferation of the malaria parasite. Here, we present the first successful cloning and expression of DOHH from P. vivax causing tertiary malaria. The nucleic acid sequence of 1041 bp encodes an open reading frame of 346 amino acids. Histidine tagged expression of P. vivax DOHH detected a protein of 39.01 kDa in E. coli. The DOHH protein from P. vivax shares significant amino acid identity to the simian orthologues from P. knowlesi and P. yoelii strain H. In contrast to P. falciparum only four E-Z-type HEAT-like repeats are present in P. vivax DOHH with different homology to phycocyanin lyase subunits from cyanobacteria and in proteins participating in energy metabolism of Archaea and Halobacteria. However, phycocyanin lyase activity is absent in P. vivax DOHH. The dohh gene is present as a single copy gene and transcribed throughout the whole erythrocytic cycle. Specific inhibition of recombinant P. vivax DOHH is possible by complexing the ferrous iron with zileuton, an inhibitor of mammalian 5-lipoxygenase (5-LOX). Ferrous iron in the active site of 5-LOX is coordinated by three conserved histidines and the carboxylate of isoleucine(673). Zileuton inhibited the P. vivax DOHH protein with an IC50 of 12,5 nmol determined by a relative quantification by GC/MS. By contrast, the human orthologue is only less affected with an IC50 of 90 nmol suggesting a selective iron-complexing strategy for the parasitic enzyme.
authors.affiliation: Institute of Pharmacogenetics, University of Duisburg-Essen, Essen, Germany.
authors.forename: Veronika Anyigoh
authors.initials: VA
authors.lastname: Atemnkeng
authors.forename: Mario
authors.initials: M
authors.lastname: Pink
authors.forename: Simone
authors.initials: S
authors.lastname: Schmitz-Spanke
authors.forename: Xian-Jun
authors.initials: XJ
authors.lastname: Wu
authors.forename: Liang-Liang
authors.initials: LL
authors.lastname: Dong
authors.forename: Kai-Hong
authors.initials: KH
authors.lastname: Zhao
authors.forename: Caroline
authors.initials: C
authors.lastname: May
authors.forename: Stefan
authors.initials: S
authors.lastname: Laufer
authors.forename: Barbara
authors.initials: B
authors.lastname: Langer
authors.forename: Annette
authors.initials: A
authors.lastname: Kaiser
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D003001:Cloning, Molecular; D016000:Cluster Analysis; D004789:Enzyme Activation; D015870:Gene Expression; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D016780:Malaria, Vivax / Q000469:parasitology; D006899:Mixed Function Oxygenases / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism*; D008969:Molecular Sequence Data; D010798:Phycocyanin / Q000378:metabolism; D010966:Plasmodium vivax / Q000145:classification / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics*; D016415:Sequence Alignment; D014158:Transcription, Genetic
chemical_list: D016859:Lipoxygenase Inhibitors; D010798:Phycocyanin; D006899:Mixed Function Oxygenases; D001094:Arachidonate 5-Lipoxygenase; C047991:deoxyhypusine hydroxylase; C063449:zileuton; D006918:Hydroxyurea